Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vilanterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.82 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | DRD1 | P21728 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.81 |
| ▸ | MC3R | P41968 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.81 |
| ▸ | GHSR | Q92847 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vilanterol SCHEMBL29352172 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL25268141 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29150309 | 0.91 | ADRB2 (0.86) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| SCHEMBL23734612 | 0.91 | ADRB2 (0.68) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Acetic Acid SCHEMBL925230 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29448201 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL925229 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL15614685 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL142630 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| SCHEMBL17031687 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649960-A1 | USE OF LONG-ACTING ß2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | Hong Kong Sxmeterol Pharmaceutical Co., Limited (HK) | 2025-11-19 | — | — | EP | claimed |
| US-20250339413-A1 | COMBINATIONS OF MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2025-11-06 | — | — | US | claimed |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | GLAXO GROUP LIMITED (GB) | 2025-08-26 | — | — | US | claimed |
| EP-4578502-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | Glaxo Group Limited (GB) | 2025-07-02 | — | — | EP | claimed |
| CN-116209654-B | Method for purifying vilantro triphenyl acetate | INKE股份公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4454645-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | Glaxo Group Limited (GB) | 2024-10-30 | — | — | EP | claimed |
| WO-2024160057-A1 | USE OF LONG-ACTING β2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | 上海市第十人民医院 | 2024-08-08 | — | — | WO | claimed |
| EP-4403231-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | Glaxo Group Limited (GB) | 2024-07-24 | — | — | EP | claimed |
| EP-3578169-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | GLAXO GROUP LTD (GB) | 2024-06-26 | — | — | EP | claimed |
| EP-3335707-B1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2024-04-17 | — | — | EP | claimed |
| US-20160095840-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2016-04-07 | — | — | US | claimed |
| US-20140116434-A1 | Dry Powder Inhaler Compositions | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | claimed |
| US-20120309725-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | claimed |
| EP-2506844-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | claimed |
| US-20110319371-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | GLAXO GROUP LIMITED | 2011-12-29 | — | — | US | claimed |
| WO-2011067212-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | claimed |
| WO-2010097114-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | claimed |
| EP-2042168-A1 | Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | claimed |
| EP-1425001-B1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095840-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRNB2, ADRA2A | ADRB2 1/4885ADRB1 14/4885ADRB3 16/4885 |
| US-20120309725-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRM3, CHRNB2 | ADRB2 1/4885ADRB1 13/4885ADRB3 17/4885 |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 8/4885ADRB3 13/4885 |
| US-20250339413-A1 | COMBINATIONS OF MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 11/4885ADRB3 14/4885 |
| US-20110319371-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | ADRB2, ADRA2C, ADRA2B | ADRB2 1/4885ADRB1 5/4885ADRB3 6/4885 |
| US-20140116434-A1 | Dry Powder Inhaler Compositions | CHRM3, CHRM2, ADRB2 | ADRB2 3/4885ADRB1 13/4885ADRB3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.